Areas of Focus

At Bristol-Myers Squibb, patients are at the center of everything we do. The goal of our cancer research is to increase quality, long-term survival and make cure a possibility. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients.

Building upon our transformative work and legacy in hematology and immuno-oncology that has changed survival expectations for many cancers, our researchers are advancing a deep and diverse pipeline across multiple modalities. In the field of immune cell therapy, this includes registrational chimeric antigen receptor (CAR) T-cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets and technologies. We are working to develop cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early to mid-stage development. Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Combining these approaches is key to delivering new options for the treatment of cancer and addressing the growing issue of resistance to immunotherapy. We source innovation internally, and in collaboration with academia, government, advocacy groups and biotechnology companies, to help make the promise of transformational medicines a reality for patients.

Bristol-Myers Squibb is committed to developing transformational therapies that will lead to long-lasting remission for patients with autoimmune diseases.  Our scientists are investigating novel targets within immune pathways to discover and develop truly innovative treatments and disease prevention approaches that better meet the needs of patients.

Bristol-Myers Squibb has a pioneering, industry-leading pipeline of targets and approaches for the treatment of autoimmune diseases that includes multiple innovative, first-in-class agents in clinical development.

Our current research is focused in areas of high unmet need including rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease.

We are expanding our innovation in cardiovascular disease to focus on underserved areas with a concentration on highly validated targets.  By leveraging real-world data, investigating new anti-coagulation agents that target multiple components of blood coagulation and pursuing novel regulators of cardiac function, we are looking for treatments that have the potential to improve cardiovascular care and in some cases, improve the function of the heart.  

Our current research is focused on heart failure and thrombosis.

We are researching medicines that have the potential to halt or reverse the progression of fibrosis, the buildup of excessive scar tissue that impairs normal organ function. We are investigating multiple mechanisms and approaches, including inhibiting pro-fibrotic factors, blocking myofibroblast activation/differentiation, and targeting matrix re-modeling and epithelial cell protection/repair.  By exploring new anti-fibrotic therapeutic mechanisms, we are hoping to advance the next wave of fibrosis medicines to patients, with the goal of improving or restoring organ function. 

We are currently advancing a pipeline of medicines to potentially treat multiple fibrotic diseases including nonalcoholic steatohepatitis (NASH), a liver disease that can lead to liver fibrosis and cirrhosis, and for which there is currently no approved therapy.  We are also discovering and developing  therapies for idiopathic pulmonary fibrosis (IPF), a progressive lung disease with very poor outcomes and limited therapeutic options. We are researching translational endpoints, prognostic biomarkers, and noninvasive imaging modalities, all with the goal of making the biggest impact for patients.

By tethering a small molecule to a biologic, antibody-drug conjugates are engineered to deliver small molecules to targeted locations using biologic monoclonal antibodies as honing mechanisms.

Biologics are large molecules produced from living organisms that may consist of a variety of organic compounds including proteins, amino acids and sugars. Most biologics have to be taken through injection because they cannot survive the digestive system.

We have a broad portfolio of CAR T and TCR constructs within our research program based on more than 15 years invested in cell therapy. We are committed to optimizing this area of research to fully capture the transformational potential for patients. 

Novel technologies that will safely and effectively deliver medicines to patients via new and potentially more desirable or convenient routes of administration.

We are working to develop a diverse array of therapeutics to target all major components of the cancer epigenome, the system that encodes expression of protein and RNA synthesis.

Gene therapy delivers modified DNA to correct, repair or replace a defective disease-causing gene. The modified DNA can be delivered through viral or non-viral mechanisms.

Millamolecules are mid-range compounds that fall in size between small molecules and biologics. Size is not the only consideration for this class, as millamolecules should also be orally available and able to interrupt protein-protein interactions.

We are working to develop cancer treatments directed at key biological pathways in protein homeostasis, including ubiquitination and degradation of proteins, a key component of this process.

Short strands of nucleic acids synthesized in the laboratory that modify cellular functions through binding to DNA or RNA.

These are organic compounds that are relatively small in size, taken orally and easily absorbed by the body.